The use of long-acting Aripiprazole in a multi-center prospective uncontrolled open-label cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index

摘要

Study design. Patients were treated with AOM at seven time points (T0-T6) in four-week intervals. Data was collected at the time points indicated. Light gray color indicates statements by the patient, dark gray color statements by the physician. AOM, Aripiprazole once-monthly; WHO-5, WHO-5 wellbeing index; GAF, Global Assessment of Functioning; TRAE, treatment related adverse events